Contact
Please use this form to send email to PR contact of this press release:
Data Lock Achieved in Trials for Suicidal Treatment; Strong Q4; Approved Stock Dividend & Share Reduction Nasdaq: NRXP
TO:
Matthew Duffy, Chief Business Officer
NRx Pharmaceuticals, Inc.
+1 484-254-6134